The 1st users participating in the testing of the final release candidate will provide information about the app’s usability and function, the Fridley, Minn.-based company said.
The Sugar.IQ app was developed to integrate Medtronic’s continuous glucose monitoring sensors with IBM (NYSE:IBM) Watson Health’s pattern recognition software, providing data about an individual’s disease-management plan.
As the app recognizes patterns in behaviors associated with glucose levels, it delivers a personalized message in real-time to the user, Medtronic said. The application also allows the user to log their meals and track how certain foods affect their glucose levels.
100 people are slated to participate in the early testing of the app, with a broader roll-out to come later this year, Medtronic said.
“We have made great progress in development of the Sugar.IQ app since unveiling the first research concepts at CES 2016,” diabetes service and Solutions president Annette Brüls said in prepared remarks. “Through our collaboration with IBM Watson Health, Medtronic will arm people with diabetes with a unique solution that could uncover previously unknown patterns while serving as a personal assistant that offers meaningful information when it matters to help transform diabetes care for greater freedom and better health.”
“The Medtronic-IBM partnership has advanced rapidly and today’s debut of the final release candidate of the Medtronic Sugar.IQ app with Watson is proof positive of that progress,” general manager for IBM Watson Health Deborah DiSanzo added. “We look forward to learning from the pilot how Watson-derived insights can potentially help people living with diabetes better manage their condition.”